Fenebrutinib BTK PPMS — First New Progressive MS Drug in 10 Years. Women 3:1 Blind Spot

Multiple sclerosis (MS) is 3x more common in women than men. Among them, primary progressive (PPMS) had no new drug in 10 years. Roche 2026.2 FENtrepid Phase III results — first BTK inhibitor fenebrutinib proved PPMS disability progression delay. Progressive MS blind spot first release.

Key Announcement

FENtrepid Phase III (PPMS, 2026.2.7):

• Fenebrutinib (brain-penetrant BTK inhibitor)
• Primary progressive MS indication
• Statistically significant disability progression delay (10-year clinical success)
• Oral·brain-penetrant
• Ad-hoc data 2026.3.2

FENhance 1·2 (relapsing MS):

• Annual relapse rate -51% (vs teriflunomide, 96 wk)
• Statistical significance (p<0.001)

MS Clinical Burden

Prevalence:

• Korea ~5,000~10,000
• Women:men = 3:1
• Onset 20~40s
• Lifelong

Types:

• Relapsing-remitting (RRMS, most common 85%)
• Primary progressive (PPMS, 10~15%)
• Secondary progressive (SPMS, RRMS progression)
• Progressive relapsing (rare)

Symptoms: Optic neuritis, paralysis·sensory abnormalities, gait disorder, cognitive decline, depression, fatigue

BTK Target - Autoimmune New Dimension

BTK (Bruton’s Tyrosine Kinase):

• B-cell signaling core enzyme
• B-cell activation·proliferation·antibody production
• Autoimmune target

Existing BTK inhibitors: Ibrutinib (blood cancer), acalabrutinib (CLL), zanubrutinib (lymphoma) → cancer indications mainly

Fenebrutinib differentiation:

• Brain-penetrant (CNS direct action)
• Oral
• B-cell + microglia simultaneous target
• First neuroimmune indication

PPMS - 10-Year Blind Spot

Existing PPMS treatment:

• Ocrevus (ocrelizumab, anti-CD20) 2017 — first PPMS indication
• But effect only some patients (relapse-associated PPMS)
• Simple progressive form ↓ effect

Why PPMS hard:

• No relapse → no drug target
• Neural degeneration predominant
• Chronic microglial activation
• B-cell + microglia simultaneous target needed → fenebrutinib

Women’s MS - Hormone·Pregnancy·Autoimmune

Women specificity:

• Pregnancy autoimmune ↓ (relapse ↓)
• Postpartum relapse ↑
• Post-menopause progression ↑
• Hormone fluctuation sensitive

Women patient blind spot:

• Progressive MS = 50~60s women ↑
• Pregnancy·lactation drug restriction
• HRT·MS drug interaction
• Depression·cognitive decline hormone influence

L71 Blind Spot Dimension - Second Axis

40 pillar connections:

• L63 drug 5 + L64 anti-CD20 → L71 BTK
• L64 cognitive reserve → L71 MS cognitive decline
• L66 AlloNK autoimmune → L71 fenebrutinib

Autoimmune progressive area first blind spot release.

Roche Fenebrutinib Pipeline

Indications: PPMS (FENtrepid), relapsing MS (FENhance 1·2), chronic urticaria (Phase 3), rheumatoid (Phase 2)

Future: MS first approval (FDA 2026~2027 expected), global staged adoption

Korean Clinical Implications

Current Korea:

• Ocrevus (ocrelizumab) insurance PPMS·RRMS
• Tysabri·Gilenya·Tecfidera for RRMS
• Progressive MS options limited

Fenebrutinib expected:

• FDA approval → Korean MFDS 1~2 years
• Insurance pricing negotiation
• Price estimate $50,000~$100,000/year

MS Women’s Guide

Post-diagnosis: MRI regular (6~12 mo), neurology + OB-GYN integrated care, pregnancy planning drug adjustment, depression·fatigue psychiatry collaboration

Daily: Vitamin D (3,000~5,000 IU), omega-3, regular exercise, stress management

Hormones: HRT doctor consult (autoimmune impact), pregnancy safe drugs (Copaxone etc), post-menopause monitoring

FAQ

Q. Is PPMS only progressive when diagnosed? A. Was before. Ocrevus (2017) → fenebrutinib (2026) sequential first drugs. Early diagnosis·drug can delay progression.

Q. BTK inhibitor side effects? A. Bleeding·infection·cardiac. Fenebrutinib = reversible BTK target → ↓ side effects expected. Clinical data analyzing.

Q. Women pregnancy·lactation? A. BTK inhibitor pregnancy·lactation contraindicated. Pregnancy planning → drug stop·switch. Doctor consult.

Q. When prescribable Korea? A. Post-FDA approval Korean MFDS 1~2 years. 2027~2028 expected.

Conclusion

Fenebrutinib BTK PPMS = progressive MS 10-year blind spot first release. Women 3:1, PPMS more severe. L71 = 40 pillars + blind spot dimension (neuroimmune 2nd axis). Korea 2027~2028 expected. Autoimmune progressive area drug·brain-penetrant·B-cell·microglia multi-target new dimension.